Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Recommendation of "Moderate Buy" by Analysts
Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has earned an average rating of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat Ratings reports. One...